IBDEI0BS ; ; 19-NOV-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15765,1,5,0)
 ;;=5^Vit B12 Deficiency (Pernicious Anemia)
 ;;^UTILITY(U,$J,358.3,15765,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,15766,0)
 ;;=282.60^^85^898^111
 ;;^UTILITY(U,$J,358.3,15766,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15766,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,15766,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,15766,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,15767,0)
 ;;=282.62^^85^898^112
 ;;^UTILITY(U,$J,358.3,15767,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15767,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,15767,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,15767,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,15768,0)
 ;;=281.1^^85^898^124
 ;;^UTILITY(U,$J,358.3,15768,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15768,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,15768,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,15768,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,15769,0)
 ;;=286.7^^85^898^54
 ;;^UTILITY(U,$J,358.3,15769,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15769,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,15769,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,15769,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,15770,0)
 ;;=289.9^^85^898^120
 ;;^UTILITY(U,$J,358.3,15770,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15770,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,15770,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,15770,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,15771,0)
 ;;=451.9^^85^898^121
 ;;^UTILITY(U,$J,358.3,15771,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15771,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,15771,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,15771,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,15772,0)
 ;;=446.6^^85^898^122
 ;;^UTILITY(U,$J,358.3,15772,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15772,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,15772,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,15772,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,15773,0)
 ;;=286.4^^85^898^125
 ;;^UTILITY(U,$J,358.3,15773,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15773,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,15773,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,15773,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,15774,0)
 ;;=204.00^^85^898^1
 ;;^UTILITY(U,$J,358.3,15774,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15774,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,15774,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,15774,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,15775,0)
 ;;=204.01^^85^898^3
 ;;^UTILITY(U,$J,358.3,15775,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15775,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,15775,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,15775,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,15776,0)
 ;;=204.10^^85^898^16
 ;;^UTILITY(U,$J,358.3,15776,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15776,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,15776,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,15776,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,15777,0)
 ;;=204.11^^85^898^18
 ;;^UTILITY(U,$J,358.3,15777,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15777,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,15777,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,15777,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,15778,0)
 ;;=201.90^^85^898^83
 ;;^UTILITY(U,$J,358.3,15778,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15778,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,15778,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,15778,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,15779,0)
 ;;=785.6^^85^898^89
 ;;^UTILITY(U,$J,358.3,15779,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15779,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,15779,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,15779,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,15780,0)
 ;;=200.20^^85^898^90
 ;;^UTILITY(U,$J,358.3,15780,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15780,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,15780,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,15780,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,15781,0)
 ;;=202.00^^85^898^92
 ;;^UTILITY(U,$J,358.3,15781,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15781,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,15781,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,15781,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,15782,0)
 ;;=200.10^^85^898^91
 ;;^UTILITY(U,$J,358.3,15782,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15782,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,15782,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,15782,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,15783,0)
 ;;=273.3^^85^898^93
 ;;^UTILITY(U,$J,358.3,15783,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15783,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,15783,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,15783,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,15784,0)
 ;;=203.00^^85^898^103
 ;;^UTILITY(U,$J,358.3,15784,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15784,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,15784,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,15784,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,15785,0)
 ;;=203.01^^85^898^105
 ;;^UTILITY(U,$J,358.3,15785,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15785,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,15785,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,15785,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,15786,0)
 ;;=238.6^^85^898^108
 ;;^UTILITY(U,$J,358.3,15786,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15786,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,15786,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,15786,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,15787,0)
 ;;=205.00^^85^898^4
 ;;^UTILITY(U,$J,358.3,15787,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15787,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,15787,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,15787,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,15788,0)
 ;;=205.01^^85^898^6
 ;;^UTILITY(U,$J,358.3,15788,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15788,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,15788,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,15788,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,15789,0)
 ;;=205.10^^85^898^19
 ;;^UTILITY(U,$J,358.3,15789,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15789,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,15789,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,15789,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,15790,0)
 ;;=205.11^^85^898^21
 ;;^UTILITY(U,$J,358.3,15790,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15790,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,15790,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,15790,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,15791,0)
 ;;=289.0^^85^898^55
 ;;^UTILITY(U,$J,358.3,15791,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15791,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,15791,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,15791,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,15792,0)
 ;;=238.4^^85^898^109
 ;;^UTILITY(U,$J,358.3,15792,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15792,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,15792,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,15792,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,15793,0)
 ;;=V58.61^^85^898^126
 ;;^UTILITY(U,$J,358.3,15793,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15793,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,15793,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,15793,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,15794,0)
 ;;=282.49^^85^898^117
 ;;^UTILITY(U,$J,358.3,15794,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15794,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,15794,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,15794,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,15795,0)
 ;;=289.89^^85^898^15
 ;;^UTILITY(U,$J,358.3,15795,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15795,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,15795,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,15795,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,15796,0)
 ;;=238.79^^85^898^88
 ;;^UTILITY(U,$J,358.3,15796,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15796,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,15796,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,15796,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,15797,0)
 ;;=287.30^^85^898^110
 ;;^UTILITY(U,$J,358.3,15797,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15797,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,15797,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,15797,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,15798,0)
 ;;=288.09^^85^898^8
 ;;^UTILITY(U,$J,358.3,15798,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15798,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,15798,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,15798,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,15799,0)
 ;;=V10.21^^85^898^61
 ;;^UTILITY(U,$J,358.3,15799,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15799,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,15799,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,15799,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,15800,0)
 ;;=284.2^^85^898^106
 ;;^UTILITY(U,$J,358.3,15800,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15800,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,15800,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,15800,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,15801,0)
 ;;=202.40^^85^898^76
 ;;^UTILITY(U,$J,358.3,15801,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15801,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,15801,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,15801,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,15802,0)
 ;;=287.49^^85^898^118
 ;;^UTILITY(U,$J,358.3,15802,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15802,1,4,0)
 ;;=4^287.49
